Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1432-0843
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma ; volume:85 ; number:5 ; day:28 ; month:3 ; year:2020 ; pages:831-842 ; date:5.2020
Cancer chemotherapy and pharmacology ; 85, Heft 5 (28.3.2020), 831-842, 5.2020

Urheber
Shemesh, Colby S.
Agarwal, Priya
Lu, Tong
Lee, Calvin
Dere, Randall C.
Li, Xiaobin
Li, Chunze
Jin, Jin Y.
Girish, Sandhya
Miles, Dale
Lu, Dan
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s00280-020-04054-8
URN
urn:nbn:de:101:1-2020070901192906865644
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:55 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Shemesh, Colby S.
  • Agarwal, Priya
  • Lu, Tong
  • Lee, Calvin
  • Dere, Randall C.
  • Li, Xiaobin
  • Li, Chunze
  • Jin, Jin Y.
  • Girish, Sandhya
  • Miles, Dale
  • Lu, Dan
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin

Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin

Fa. Ch.P. Heinrich - Paris

Archivale

Fa. Ch.P. Heinrich - Paris

Wappen + CHP? = Cantus, S.21+24

Abschnitt

Wappen + CHP? = Cantus, S.21+24

Wappen + CHP? = Cantus, S.21/24

Abschnitt

Wappen + CHP? = Cantus, S.21/24

Wappen + CHP? = Cantus, S.21/24

Abschnitt

Wappen + CHP? = Cantus, S.21/24

CHP İstanbul İl kongresi 1968

Monografie

CHP İstanbul İl kongresi 1968

Polatuzumab Vedotin: First Global Approval

Polatuzumab Vedotin: First Global Approval

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Verbundene Objekte